Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
about
Chronic myeloid leukemia: reminiscences and dreamsThe indications for allogeneic stem cell transplantation in myeloid malignancies.Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients.Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia.Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.The European LeukemiaNet: achievements and perspectives.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaPrior exposure to imatinib does not impact outcome of allogeneic hematopoietic transplantation for chronic myeloid leukemia patients: a single-center experience in chinaChronic myelogenous leukemia: role of stem cell transplant in the imatinib era.The role of stem cell transplantation for chronic myelogenous leukemia in the 21st centuryJanus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosisReduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcomeImpact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.Extramedullary Involvement by Chronic Myelogeneous Leukemia in Five Patients With Unusual Clinicopathologic Features: A Review of the Effectiveness of Tyrosine Kinase InhibitorsOutcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort AnalysisPediatric chronic myeloid leukemia is a unique disease that requires a different approachEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study.Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.Quality of life in chronic myeloid leukaemia patients after haematopoietic cell transplantation pretreated with second-generation tyrosine kinase inhibitors.Stem cell transplant for chronic myeloid leukemia in the imatinib eraTreatment of chronic myeloid leukemia when imatinib fails.Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.The EBMT risk score.Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.Is there a role for allogeneic transplantation in chronic myeloid leukemia?Ever-advancing chronic myeloid leukemia treatment.Treatment recommendations for chronic myeloid leukemiaOutcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.Myeloid sarcoma as the presenting symptom of chronic myelogenous leukemia blast crisis.An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.The role of hematopoietic stem cell transplantation in chronic myeloid leukemia.
P2860
Q26748769-CE75FA9A-D4F7-40B4-A2DB-DF7BE292D157Q30316611-D1D4EF6B-DE47-4F5F-B0DD-466118A80B05Q30891587-FF573A66-21FC-4D46-B32E-AE1122AB137EQ33397477-5D751D4A-1208-4458-9CDD-11C45F3F9A68Q33729437-8D61D4CD-2413-4DA5-8CD1-95D298757DDAQ33747792-5C015175-05A3-4B01-8E8D-DF98630993DAQ33886172-3BC1F988-F3C3-43D9-A9EB-8BD0BC6B63F5Q33926114-A594E4C7-8B37-44AB-94A1-4930810650EFQ34451619-C4BEEDF1-C5FA-40E1-9D95-5DF0FD4D6FE0Q34522789-35B51A98-75D2-4C7C-A828-02849354DDD3Q35480678-E7DFCBCD-8D06-4E23-B968-E81EC1FD8C4FQ35633858-3EB4DDFC-89D5-4F21-9B2D-6911AEB2C48AQ35634865-50B0D9D6-866E-4114-ADC4-5F8CDB498BDBQ35735663-3A31D256-C0A6-4FD9-A11E-F935BB524696Q35953410-30572D81-083E-4385-94C1-DA5E2FB402B2Q36059184-31A237E9-4FBB-4E96-8C95-0741D0247F2DQ36070796-9E497C7E-5E93-4B56-B42B-E1E02343FA22Q36094702-7C30B7E8-BB9A-4658-AE1B-1797CB09312EQ36309977-A0A62737-ADCA-427A-A736-7205393568DAQ36650103-1931033D-79F4-4C1D-B29D-9FD9718D9220Q36856998-D5593079-D3FF-4210-A285-242F76A14DF8Q36928803-9F42A53D-2E84-43D4-B41E-AF2972DA09AAQ37025981-C5BCF9D6-C6BD-4E91-B641-7617F39346CAQ37026032-8B043FAE-FD7D-47EF-BEB5-8C72BAC32B38Q37060673-37C71967-8361-4501-B877-C537DED6C4B4Q37497977-309EC5D4-A2F6-440B-AC5F-6E0A6A20CBFAQ37625289-45862C7C-3BC5-4C75-88ED-9B6972020AC1Q37727668-41B27300-CB34-4FF5-85C0-5EEAAF14EFB7Q37793491-DC639A22-F1F9-4DBA-B69F-17717436E059Q37827875-B2E148CA-986F-4103-A513-7CBB0C958DBEQ37853793-87B6D771-CC27-42D6-868D-BD20746C5CFCQ37885167-57DBE465-855B-4A98-9269-D05E80AE8788Q38139571-05FCB81C-CD82-412A-B2A5-96F04F45E26AQ38161964-01FB3E5B-134F-467C-B49C-882506860194Q38164565-64046D66-7C73-4532-922B-976F7CFC52D2Q38181112-480E4211-8515-4C0E-957C-1797D6DDFD78Q38216677-EC0D7FE4-CB7E-4CFC-A5C2-557C1570DDE3Q38225112-3674D584-A9DB-4692-9262-951C18955EE2Q38236642-63E401B6-BEAC-4B46-AEBD-E4F7B91E4A19Q38392690-CE1D65DC-CE98-43AA-9363-8547BBE4FB6E
P2860
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Allogeneic hematopoietic stem ...... andomized German CML Study IV.
@en
type
label
Allogeneic hematopoietic stem ...... andomized German CML Study IV.
@en
prefLabel
Allogeneic hematopoietic stem ...... andomized German CML Study IV.
@en
P2093
P50
P1433
P1476
Allogeneic hematopoietic stem ...... andomized German CML Study IV.
@en
P2093
Anthony D Ho
Armin Leitner
Axel R Zander
Brigitte Schlegelberger
Christiane Falge
Dietrich W Beelen
Donald Bunjes
Ernst Holler
German CML Study Group
Günter Schlimok
P304
P356
10.1182/BLOOD-2009-08-237115
P407
P577
2009-11-18T00:00:00Z